voriconazole has been researched along with quinidine in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ghosh, I; Manoharlal, R; Prakash, O; Prasad, R; Puri, N; Sharma, M | 1 |
| Brown, AM; Bruening-Wright, A; Kramer, J; Kuryshev, YA; Myatt, G; Obejero-Paz, CA; Verducci, JS | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chen, F; Chen, W; Lan, L; Li, B; Li, J; Liu, Y; Mao, F; Ni, S; Wei, H; Zhu, J | 1 |
| Cheng, M; Hao, C; Jiang, X; Su, X; Wei, P; Wu, M; Zhang, X; Zhao, D; Zhao, L; Zhao, S | 1 |
| Cheng, M; Cui, H; Jiang, H; Li, S; Liu, L; Su, X; Sun, Y; Wu, T; Yin, W; Zhang, Y; Zhao, D; Zhao, L; Zheng, Y | 1 |
| Hyland, R; Jones, BC; Smith, DA | 1 |
1 review(s) available for voriconazole and quinidine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
10 other study(ies) available for voriconazole and quinidine
| Article | Year |
|---|---|
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
Topics: Candida albicans; Membrane Transport Proteins; Saccharomyces cerevisiae; Structure-Activity Relationship; Substrate Specificity | 2010 |
MICE models: superior to the HERG model in predicting Torsade de Pointes.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Theoretical; Patch-Clamp Techniques; Predictive Value of Tests; Torsades de Pointes | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Novel Terminal Bipheny-Based Diapophytoene Desaturases (CrtN) Inhibitors as Anti-MRSA/VISR/LRSA Agents with Reduced hERG Activity.
Topics: Animals; Drug Design; Enzyme Inhibitors; ERG1 Potassium Channel; HEK293 Cells; Hep G2 Cells; Humans; Inhibitory Concentration 50; Methicillin-Resistant Staphylococcus aureus; Mice; Oxidoreductases; Rats; Safety; Solubility; Structure-Activity Relationship; Water | 2018 |
Design, synthesis and evaluation of benzoheterocycle analogues as potent antifungal agents targeting CYP51.
Topics: Antifungal Agents; Aspergillus fumigatus; Binding Sites; Candida albicans; Catalytic Domain; Cryptococcus neoformans; Drug Design; Drug Resistance, Fungal; Drug Stability; Fluconazole; Fungal Proteins; Gas Chromatography-Mass Spectrometry; Humans; Microbial Sensitivity Tests; Molecular Docking Simulation; Protein Isoforms; Sterol 14-Demethylase; Sterols; Structure-Activity Relationship; Triazoles | 2018 |
Design, synthesis and evaluation of novel 5-phenylthiophene derivatives as potent fungicidal of Candida albicans and antifungal reagents of fluconazole-resistant fungi.
Topics: Antifungal Agents; Candida albicans; Dose-Response Relationship, Drug; Drug Design; Drug Resistance, Fungal; Fluconazole; Fungicides, Industrial; Humans; Microbial Sensitivity Tests; Molecular Structure; Structure-Activity Relationship; Thiophenes | 2021 |
Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole.
Topics: Antifungal Agents; Chromatography, High Pressure Liquid; Cyclic N-Oxides; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Humans; In Vitro Techniques; Ketoconazole; Microsomes, Liver; Oxidation-Reduction; Pyrimidines; Quinidine; Sulfaphenazole; Theophylline; Triazoles; Voriconazole | 2003 |